Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess

Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess

IntroductionEnfortumab vedotin (EV) and Erdafitinib are effective therapeutic drugs for bladder cancer patients following post-chemotherapy and immunotherapy. This study assessed adverse drug reactions (ADRs) from both drugs, comparing their safety profiles to guide clinical use.MethodsA retrospecti...

Full description

Bibliographic Details
Main Authors: Yuanbin Huang, Meiqi Xu, Xinmiao Ma, Wei Wang, Chen Shen, Fei Liu, Zhiqi Chen, Jiawen Wang, Qian Guo, Xiancheng Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Pharmacology
Subjects:
adverse drug reaction
Enfortumab vedotin
Erdafitinib
pharmacovigilance
spontaneous reporting
WHO-VigiAccess database
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1503154/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1503154/full

Similar Items